TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PARAGARD T 380A

COPPER
Approved 1984-11-15
6
Indications
--
Phase 3 Trials
41
Years on Market

Details

Status
Prescription
First Approved
1984-11-15
Routes
INTRAUTERINE
Dosage Forms
SYSTEM

Companies

Active Ingredient: COPPER

PARAGARD T 380A Approval History

Loading approval history...

What PARAGARD T 380A Treats

6 FDA approvals

Originally approved for its first indication in 1984 . Covers 6 distinct patient populations.

  • Other (6)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PARAGARD T 380A FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Paragard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years.

PARAGARD T 380A Patents & Exclusivity

Exclusivity: Jun 2027

Exclusivity

D-193 Until Jun 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.